Aktieanalyser från populära analyshus

14 Nov 2025 13:46

Integrum: Better preliminary Q2 results than expected - Redeye

Integrum

14 Nov 2025 13:06

Rättelse VBG Group: Ökning på alla affärsområden - Analysguiden

VBG Group redovisade en omsättningsökning på 7,5 % till 1 362 MSEK under Q3 2025, varav 6,3 % var or...

VBG Group

14 Nov 2025 11:48

VBG Group: Stabilisering på plats - Analysguiden

Avensia: October sales figures looking solid - Redeye

Redeye comments on Avensia’s October sales figures.

AlzeCure Pharma (Q3 Review): Clinical phase IIa study in focus - Redeye

AlzeCure Pharma

14 Nov 2025 11:37

Ogunsen: Shows early demand uptick - ABG

* Sales -9% and EBIT -18% vs ABGSCe * Weak utilisation in the consultant market * Expecting market s...

OXE Marine: GM, new engine supplier - Redeye

Dala Energi (Q3 Initial take): No drama - Redeye

Redeye comments on Dala Energi’s Q3 report, which presented no real surprises.

Finnair: Aiming to capture RASK potential - Evli

Finnair

14 Nov 2025 09:24

Energy Save: Should be better from here - ABG

* Q3 was softer, but better cost control was positive * '25e-'27e sales cut by 15-22% on lower volum...

Paxman Q3 (Initial take): Softer sales but better costs than expected - Redeye

Smart Eye (Q3 Initial take): Bang In-Line and a Strong Outlook - Redeye

Redeye notes that Smart Eye’s Q3 was very in-line with our expectations, with only a minor deviation...

Guard Therapeutics (Q3 Review): Waiting for the fog to lift - Redeye

Crunchfish: Breakthrough integration sets stage for commercial expansion - Emergers

Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...

BICO (Q3 Review): A return to organic growth and adjusted EBITDA profitability - Redeye

Better Collective (Q3 Review): On track for organic growth recovery - Redeye

Redeye updates on Better Collective after its Q3-report where leave our estimates largely unchanged ...

Moberg Pharma (Q3 Review): European footprint expanded, strengthening mid-/long-term outlook - Redeye

VEF (Initiating coverage): Redeye talks with CEO Dave Nangle - Redeye

Redeye interviews VEF’s CEO, Dave Nangle. Dave provides an overview of the company, its track record...

Surgical Science (Q3 review): Soft margins and cash conversion - Redeye

Fable Media Group (Q3 Review): Moving Past Brazil and Gearing Up for 2026 - Redeye

Fable Media Group delivered a soft Q3 in line with the preliminary figures, but the underlying trend...

Ferronordic: A step in the right direction - Nordea

Oncopeptides: Key Takeaways from the Capital Markets Update - Redeye

Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.

Oncopeptides

13 Nov 2025 15:49

Ferronordic: Sequentially better across the board - ABG

Mendus (Q3 review): Executing on updated clinical strategy - Redeye

Redeye provides its comment on Mendus’ Q3 2025 report.

Isofol Medical: Strengthened patent protection - Redeye

Isofol Medical

13 Nov 2025 14:04

Catella: Optimistic outlook maintained - ABG

* Q3 a bump in the road * Estimates down given more cautious view on activity pick-up * 2025e-'27e E...

Alzinova (Q3 review): Regulatory progress in anticipation of a deal - Redeye

Trianon: Omotiverad rabatt på kvalitetsbestånd - Mangold Insight Analys

Fastighetsbolaget Trianon levererade ett starkt tredje kvartal med 33 procent högre förvaltningsresu...

Trianon

13 Nov 2025 10:57

Angler Gaming Group: Lönsamheten i kvartalet var över förväntan - Analysguiden

Angler Gaming